The D-BIOMARK trial was designed to investigate the biological effects of denosumab in patients with HER2-negative early breast cancer as a proof of concept for its potential antiproliferative, proapoptotic, and immunomodulatory effects on these tumors and their microenvironment, beyond its bone-related effects. Here, ERBB2 is linked to breast cancer.